In order to develop the product, Heska leveraged intellectual property developed by Dr. Mary Morris & Associates, located in La Crosse, Wis. The advance will support Heska’s production of allergy treatments delivered under the tongue of an animal.
It is estimated that between 10 and 15 percent of dogs are affected by allergies, according to Michael McGinley, president and CEO of Heska.
“This expanded commitment to our allergy franchise is consistent with our strategy of offering valuable products in important areas of veterinary medicine,” McGinley said. Because the new treatment can be administered under an animal’s tongue, it improves the likelihood of pet owner compliance, he said.